Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 80/100

Failure Rate

44.4%

4 terminated/withdrawn out of 9 trials

Success Rate

50.0%

-36.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

75%

3 of 4 completed trials have results

Key Signals

3 with results

Enrollment Performance

Analytics

Phase 1
7(77.8%)
Phase 2
2(22.2%)
9Total
Phase 1(7)
Phase 2(2)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials
NCT01631279Phase 1Terminated

A Dose Escalation Trial of PR610 Treating Patients With Solid Tumors

Role: lead

NCT00862082Phase 1Terminated

Randomized Phase 1/2 Open-Label Trial of PR104 and Sorafenib in Patients With Advanced Hepatocellular Carcinoma (HCC)

Role: lead

NCT00862134Phase 2Terminated

Randomized, Multi-center, Open-label, Study of PR104 Versus PR104/Docetaxel in Non-Small Cell Lung Cancer (NSCLC)

Role: lead

NCT00544674Phase 2Terminated

PR104 in Treating Patients With Previously Untreated or Relapsed Small Cell Lung Cancer

Role: lead

NCT00349167Phase 1Completed

PR-104 in Treating Patients With Advanced Solid Tumors

Role: lead

NCT01037556Phase 1Unknown

PR104 in Treating Patients With Refractory/Relapsed Acute Leukemia

Role: lead

NCT00616213Phase 1Completed

PR104 and G-CSF in Treating Patients With Solid Tumors

Role: lead

NCT01358227Phase 1Completed

A Phase I Dose Escalation Trial of PR104 Given Weekly in Subjects With Solid Tumors

Role: lead

NCT00459836Phase 1Completed

PR-104 and Docetaxel or Gemcitabine in Treating Patients With Solid Tumors

Role: lead

All 9 trials loaded